CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).

HTD Health Launches Healthcare AI Practice Led by Erkin Ötle

Erkin Otles – AI Practice Lead – HTD Health What You Should Know: – HTD Health, a New York-based company specializing in virtually-enabled care, EMR integration, and

September 6, 2023

Gaza polio vaccination drive must include measles shots

We have each worked on childhood vaccination programs in both development and humanitarian emergency settings for more than 40 years. In that time, we have

September 6, 2024

Q&A: Exploring the challenges behind oncology trials – Pharmaceutical Technology

Share this article Pauline Frank reflects on her talk at the 2023 CTO Europe conference and highlights some of the key issues in running oncology

January 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.